Context

Abivax is a French-listed, late-stage clinical biotech company mobilizing the immune system to treat patients with inflammatory diseases, viral infections and cancer.

Abivax leverages its immune-enhancing and antiviral platforms to optimize and develop drug candidates to treat a range of conditions: ABX464 for ulcerative colitis, Crohn’s disease, rheumatoid arthritis, other inflammatory diseases, Covid-19 and HIV; and ABX196 for liver cancer.

Abivax was founded by Truffle Capital and is now backed by Sofinnova.

Follow-on Offering proceeds will be mainly used to progress clinical trials in the following areas: to complete Phase 2b and prepare Phase 3 of ABX464 in ulcerative colitis (UC); complete Phase 2a of ABX464 in rheumatoid arthritis (RA); complete the Phase 2b/3 of ABX464 in Covid-19 indications and prepare for regulatory filings, market access and commercialization, if clinical data are positive; prepare Phase 2b/3 of ABX464 in Crohn’s disease.

Abivax_website_tombstone

About Abivax

Abivax, a clinical-stage biotechnology company, is mobilizing the body’s natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment C (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.

Discover Abivax

Olivier Garnier

Investment Banking

Olivier Garnier photo

Eric Le Berrigaud

Equity & Research

Eric Le Berrigaud photo

Pierre Kiecolt-Wahl

Equity Capital Markets

Pierre Kiecolt-Wahl photo

Cosme Rosellini

Equity Capital Markets

Cosme Rosellini photo

Pierre Sertour

Equity Capital Markets

Pierre Sertour photo

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center